

**IMAGIN MEDICAL INC.**  
**MANAGEMENT DISCUSSION & ANALYSIS**

**For the Six Months Ended March 31, 2018**

**Directors and Officers as at April 25, 2018**

**Directors:**

Robin Atlas  
Steve Chan  
Ken Daignault  
Jim Hutchens  
John Vacha

**Officers:**

President & C.E.O. – Jim Hutchens  
C.F.O. & Secretary – John Vacha

**Contact Names:**

Jim Hutchens  
John Vacha

**Telephone Number:**

617-571-6006  
617-448-8379

**IMAGIN MEDICAL INC.**

**MANAGEMENT DISCUSSION & ANALYSIS**

For the Six Months Ended March 31, 2018

**1.1 Date of This Report**

April 25, 2018

This Management's Discussion & Analysis ("MD&A") of Imagin Mining Inc. for the six months ended March 31, 2018 has been prepared based on information available to us as of April 25, 2018. This discussion should be read in conjunction with the Condensed Interim Consolidated Financial Statements of the Company and notes attached thereto for the six months ended March 31, 2018 included herewith, all of which are available at the SEDAR website at [www.sedar.com](http://www.sedar.com).

*This MD&A includes certain statements that may be deemed "forward-looking statements". All statements in this discussion, other than statements of historical facts, that address activities and events or developments that the Company expects, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include product development timing, government regulatory approvals, hospital reimbursement, continued availability of capital and financing and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Reported currency is stated in Canadian dollars.*

**1.2 Overall Performance**

*Description of Business*

Imagin Medical Inc. (formerly Expedition Mining Inc.) is incorporated in the Province of British Columbia and its previous principal business activity was the acquisition and exploration of resource properties. On February 9, 2016, the Company completed the acquisition of BSS Life Sciences Inc. ("BSS"). BSS holds the intellectual property rights to a proprietary imaging technology developed for extremely accurate visualization of cancers. In connection with the acquisition, the Company changed its name to Imagin Medical Inc. and now focuses on the research, develop and commercialize medical devices in the bio-chemistry industry.

*License Agreement*

By way of a Licence Agreement dated May 20, 2015, BSS was granted an exclusive, nontransferable, royalty-bearing license by Lawrence Livermore National Security, LLC (LLNS), to use LLNS's patents and intellectual property rights to manufacture and sell products and services pertaining to in-vivo imaging applications.

Under the License Agreement, BSS must:

- complete a commercial prototype by December 31, 2016 (First prototype completed);
- complete submissions for United States Food and Drug Administration (“FDA”) approval by December 31, 2017 (Not Completed and extended to Dec 31, 2019);
- achieve first commercial sales (“FCS”) in the United States within one year of achieving the FDA approval; and
- achieve gross cumulative sales revenues from the sales of licensed products of at least \$10,000,000 within the first three years of achieving FCS.

The sales requirements may be amended and/or extended at the written request of BSS to LLNS, based upon legitimate business reasons specified in reasonable detail in such written request.

BSS must pay certain fees to LLNS for the licence, being (all amounts are in US dollars):

- (i) a nonrefundable issue fee of \$100,000 payable as follows:
  - \$10,000 upon the date of execution of the Agreement (June 22, 2015; paid);
  - \$30,000 by November 22, 2015 (paid);
  - \$30,000 by January 22, 2016 (paid); and
  - \$30,000 by March 22, 2016 (paid).
- (ii) an earned royalty of 3% of net sales, subject to minimum annual royalties of:

<b>Calendar year</b>	<b>Minimum annual royalty</b>	<b>Due date</b>
2017	\$5,000	Paid October 19, 2017
2018	\$10,000	Paid February 28, 2018
2019	\$10,000	February 28, 2019
2020 and thereafter	\$25,000	February 28 of each year

- (iii) a nonrefundable U.S. Maintenance Patent Fee of \$45,000 to be paid as follows:
  - \$15,000 on or before February 28, 2016 (paid);
  - \$15,000 on or before February 28, 2019; and
  - \$15,000 on or before February 28, 2023

### ***The Technology***

#### *i/Blue Imaging System used in conjunction with imaging agents*

The Company believes it will establish a “new standard of care” for urologists and address the limitations of the current technology in the early detection of bladder cancer through endoscopes. The development team has successfully retrofitted an original prototype with significant improvements to its internal components. Image processing and display software has been developed that integrates state-of-the art, high resolution cameras and patented, image-blending technology with other proprietary elements. The result will be a composite image highlighting the cancer lesions within the bladder in high definition, estimated to be 100 times more sensitive than currently available systems.

These advancements are expected to expose the specifics of the image in less than 15 minutes versus the full hour required by conventional fluorescence systems. Premalignant lesions and tumor tissue along the margins will be highlighted and identified for removal, potentially reducing the chances of recurrence. Producing superior imaging quality in less than one quarter of the time of current systems is expected to increase the efficiency of the operating room and reduce healthcare costs by potentially enabling follow-up exams to be performed in the less-expensive physician's office.

In addition, the surgeon will no longer need to switch back and forth between two images. The i/Blue's specialized cameras will employ *Simultaneous Acquisition of Differing Images*, a patented technology which automatically blends the white and fluorescence images into one, putting the cancer into context and enabling the surgeon to better visualize and resect the cancer.

The i/Blue's patented technology can be seamlessly adapted to most endoscopes on the market today.

#### *Benefits of the i/Blue Imaging System*

- “Sees” the cancer in less than 15 minutes vs. one hour
  - Optics 100 times more sensitive
- No switching back and forth
  - *Simultaneous Acquisition of Differing Images* blends the white light and fluorescence images into one
  - Puts the cancer into context within the bladder
  - Enables surgeon to better visualize and resect the cancer, helping to reduce recurrence
- Adapts to blue light method with added unique fluorescence wavelengths

#### *Future Development*

##### *i/Vision Imaging System*

The i/Vision Imaging System, the Company's next advancement, will be expanded to incorporate multiple illumination sources so that detection of different contrast agents can be realized by the same system. Such a system can be custom made or designed to accommodate the most commonly used fluorescing contrast agents, such as those currently available based on the emission of Protoporphyrin IX (PpIX) and Indocyanine green (ICG). This instrument will enable expansion into multiple endoscopic procedures, cancerous or noncancerous conditions, such as laparoscopic (general and gynecology), colorectal and thoracic.

##### *i/Red Imaging System*

The i/Red Imaging System, an additional advancement, will use a unique method to illuminate the cancer with red light and completely eliminate the need for imaging agents. This breakthrough technology uses only fluorescence produced by the body and the tumor itself. This product requires specialized light sources, sensitive cameras and a unique optical design. The i/Red Imaging System will dramatically broaden the market to all cancer specialists using any type of scopes.

#### *Benefits of the i/Red Imaging System*

- Uses only the fluorescence produced by the body and the tumor itself
- Potentially reaches and detects cancer in other parts of the body where imaging agents cannot be practically administered

- Contrast between normal/cancer tissue is potentially related to the difference in porphyrin content within the cells, which in turn relates to the difference in metabolism of the cancer cells
- Like i/Blue, i/Red will employ simultaneous acquisition of differing images, adapt to most endoscopes and will be orders of magnitude more sensitive

### ***The Strategy***

The Company will position the i/Blue Imagin System as the “new standard of care” in bladder cancer by differentiating its dramatic technical, clinical and economic improvements over current technologies.

The system’s advanced, ultrasensitive optics will produce images in less than 15 minutes vs. the full hour required by today’s current technology. The patented *Simultaneous Acquisition of Differing Images* will automatically blend the white light and fluorescence images into one, eliminating the need for the surgeon to switch back and forth, a capability that doesn’t exist today. This feature automatically places the cancer into context within the bladder, providing a more expedient image for the surgeon. These improvements make the i/Blue system practical, not only for the O.R., but also for the less-expensive physicians’ office, potentially reducing recurrence and healthcare costs, as well as expanding the market to other procedures where endoscopes are used. The i/Blue technology is adaptable to most endoscopes currently on the market, which will be of strategic interest in forming partnerships with existing dominant corporations.

The Company is planning the commercialization of the i/Blue Imaging System for mid 2019 and believes it will achieve rapid revenue growth. Over the course of the next eighteen months, the Company will begin a marketing program comprised of participating in trade shows, conducting focus groups, developing physician champions and establishing four Centers of Excellence. The marketing program will also continue to build on management’s current relationships with seven key successful independent sales representatives who currently call on urologists.

### ***Imagin Medical’s Intellectual Property***

The Company, through its wholly owned subsidiary (BSS Life Sciences) has secured an exclusive license from Lawrence Livermore National Security, LLC (LLNS) to commercialize the technology invented by Dr. Stavros Demos. This licence agreement includes the three issued patents and one pending patent application on technology related to exclusive spectroscopic imaging for cancer and other medical applications. These include:


1. Issued U.S. Patent 7,149,567 - Near-Infrared Spectroscopic Tissue Imaging for Medical Applications
2. Issued U.S. Patent 7,257,437 - Autofluorescence Detection and Imaging of Bladder Cancer Realized Through a Cystoscope
3. Issued U.S. Patent 8,285,015 - Simultaneous Acquisition of Differing Image Types
4. Pending U.S. Patent Application No. 13/601,918 - Simultaneous Acquisition of Differing Image Types

**Product Development Plan and Timing**

The Company is planning for the commercialization of its first product, the i/Blue Imaging System, in mid-2019.

The Company continues to work against its plan that will be completed with the support of Dr. Stavros Demos, the inventor, currently a Senior Scientist and Group Leader of the Optical Materials Group at the University of Rochester Laboratory for Laser Energetics (LLE). In 4Q of 2016, the Company completed the development of the Alpha Prototype. The Institutional Review Board of the University of Rochester granted approval for the first in-human Research Study using the i/Blue Imaging System at its Medical Center in 3Q 2017. Enrollment for the 10-patient study is expected to begin in 1Q 2018 and all ten procedures to be completed within four months. The study will be open for an additional nine months for subject follow-up.

The Company hired Optel, Inc, an optical product design firm located in Rochester, New York, to design the i/Blue Imaging System for manufacturability and commercialization. Plans include reducing the size of the current prototype by 70%, enabling the i/Blue system to be used as a mobile device that can be easily moved between different operating rooms and physicians’ offices. The Company plans to begin the FDA approval process in 2Q 2018, followed by additional clinical trials in 3Q and 4Q 2018 at the University of Rochester as well as UC Davis Comprehensive Cancer Center. Once these separate, concurrent steps are completed, commercialization is planned to begin in mid 2019. See timeline below.



### ***Highlights from Oct 1, 2017 up to the date of this report***

The Company announced the following:

- closed a non-brokered Private Placement with the issuance of 20,000,000 units priced at \$0.05 per unit for gross proceeds of \$1,000,000. Each Unit of this Private Placement will consist of one common share of the Company and one common share purchase warrant (“Warrant”), each warrant entitling the holder to acquire one additional common share of the Company at a price of \$0.10 within the 12 months.
- closed a \$120,000 financing to raise funds to be used for the Company’s communications program. The funds raised pursuant to the Financing will be specifically targeted for a communications and marketing program, allowing the Company to continue to maintain its existing cash for product development and commercialization. The Financing will consist of 800,000 units (the “Units”) at a price of \$0.15 per Unit, each Unit to be comprised of one common share and one half of one common share purchase warrant (the “Warrants”). Each whole Warrant will be exercisable into one common share in the equity of the Company (the “Warrant Shares”) at an exercise price of \$0.25 per Warrant Share. The Warrants expire one year from date of issuance.
- announced that Roger J. Buckley, M.D., Chief of Urology at North York General Hospital in Toronto, Vice President of the International Bladder Cancer Group (IBCG), and a member of Imagin’s Scientific Advisory Board, attended the 37th Congress of the Society of International Urology held October 19 through 22 in Lisbon, Portugal.
- confirmed that experts in the field of urology concur that one reason for the high recurrence rate after transurethral resection (TUR), is that some cancer not seen was left behind by the surgeon. The Company’s i/Blue Imaging System is expected to reduce the time for physicians to visualize the cancer to ten minutes.
- announced that Optel, Inc., the Company’s optical product-design firm, will begin the redesign of the i/Blue Imaging System prototype for manufacturability and commercialization. The redesign will be concurrent with the first in-human research study using the i/Blue prototype that is anticipated to begin shortly at the University of Rochester Medical Center.
- announced the first in-human Research Study using the i/Blue Imaging System is open for enrollment and recruitment has begun at the University of Rochester Medical Center.
- announced the grant of an aggregate of 2 million stock options to certain directors, officers and consultants at an exercise price of \$0.25, exercisable for a period of five years.
- announced the approval of a bonus payable of 5 million shares to the President and CEO for his part in the Company’s recent success in advancing its technology with the University of Rochester and raising much needed working capital funds.
- announced that the Company has received more than \$1,000,000 through the exercising of warrants by long-term investors.
- announced that it hired John Vacha as the Company’s new CFO.
- announced that a number of clinical procedures have been performed and technical progress continues as this investigative research program focuses on the rapid interoperative identification of bladder cancer.
- announced the closing of a non-brokered private placement for \$200,000 through the issuance of 625,000 shares at \$0.32 for the Company’s ongoing communications and marketing program.

- announced the closing of a non-brokered private placement for \$240,000 through the issuance of 888,889 shares at \$0.27 for the Company’s ongoing communications and marketing program.
- announced that further to its press release of April 3, 2018, the Company closed its non-brokered Private Placement (Tranche 1 and 2) through the issuance of 17,919,820 units (the “Units”) priced at \$0.22 per Unit for gross proceeds of \$3,942,361. Each Unit of this Private Placement will consist of one common share of the Company and one common share purchase warrant (“Warrant”), each Warrant entitling the holder to acquire one additional common share of the Company at a price of \$0.38 for 24 months from the date of issue.
- Total finders’ fees will be paid in the form of cash in the amount of \$223,267 and 1,117,110 finders’ warrants (exercisable at \$0.38 per share for 24 months). All securities issued will be subject to a four-month hold period.

At the date of this report, the Company currently has 126,034,738 issued and outstanding Shares; 1,100,000 Acquisition Warrants; 34,072,207 Finance Warrants; 1,653,370 finders’ warrants; and 9,875,000 incentive stock options.

### 1.3 Selected Annual Information

The highlights of financial data for the Company for the two most recently completed financial years are as follows:

	<u>Imagin</u> <u>Medical Inc.</u> <u>Sept. 30, 2017</u>	<u>Imagin</u> <u>Medical Inc.</u> <u>Sept. 30, 2016</u>
(a) Loss before other items		
(i) Total loss	\$1,377,537	\$1,774,908
(ii) Loss per share – basic	\$0.03	\$0.07
(iii) Loss per share – diluted	\$0.03	\$0.07
(b) Net loss		
(i) Total loss	\$1,542,102	\$2,259,571
(ii) Loss per share – basic	\$0.03	\$0.08
(iii) Loss per share – diluted	\$0.03	\$0.08
(c) Total assets	\$389,644	\$351,161

### 1.4 Results of Operations

#### *Discussion of Operations and Financial Condition*

On February 9, 2016, the Company completed the acquisition BSS Life Sciences Inc. (“BSS”). In connection with the closing, the Company issued 26,500,000 common shares to the shareholders of BSS (see note 10). As a result of the exchange, the transaction resulted in a reverse asset acquisition. Accordingly, BSS will be considered the continuing entity for accounting and financial reporting purposes and Imagin Medical Inc. (“Imagin”), the continuing public company, being the corporation acquired. As Imagin was a public ‘shell’ company, there was, in the opinion of management, no basis to reliably measure the consideration paid for it by BSS, other than to use the current carrying values of its assets acquired and liabilities assumed.

Accordingly, the purchase price allocation of the acquisition is based on the fair value of the net liabilities assumed, which was charged to operations as a listing expense.



The fair values of assets acquired and liabilities assumed are as follows:

Cash	\$	1,000
Other assets		120,301
Accounts payable		(504,077)
Net liabilities acquired (Listing expense)	\$	(382,776)

For comparative purposes, the financial statement continuity presented herein is that of BSS. However, the continuity of issued share capital, prior and subsequent to the date of the acquisition, is that of Imagin.

The following should be read in conjunction with the condensed interim consolidated financial statements for the six months ended March 31, 2018 and notes attached hereto.

During the six months ended March 31, 2018, the Company reported a net loss of \$3,989,309 (\$870,062 – March 31, 2017). The Company incurred the following major expenditures:

1. Consulting fees – Total \$702,926 (Increased by \$506,359)
  - Marketing and Investor Relations – The Company engaged numerous consultants to provide services primarily related to raising capital and public relations, specifically, internet marketing, research reports, news and press releases and their distribution. The continues with its ongoing communications and marketing program, allowing the Company to continue to maintain its existing cash for product development and commercialization.
2. Corporate & administration fees – Total \$55,727 (Increased by \$13,663)
  - The increase is mainly related to the numerous private placements the Company closed during the period.
3. Legal & accounting – Total \$92,666 (Increased by \$32,313)
  - During the second quarter, the Company hired John Vacha as the new Chief Financial Officer. Jorge Avelino, the former Chief Financial Officer continues to work with the Company doing all the regulatory and accounting functions.
4. Management fees – Total \$1,329,464 (Increased by \$1,144,556)
  - During the second quarter, the Company paid the President a bonus of 5,000,000 as per corporate resolution dated August 15, 2017. The Company recorded the transaction at a price of \$0.235 per share, which was the closing price of the stock at the date of issuance.
5. Shareholder's communication & promotion – Total \$36,243 (Increased by \$24,110)
  - The increase is mainly related to the continuous fund raising and ongoing communication.
6. Travel, meals & entertainment - Total \$25,982 (Increased by \$21,293)
  - The increase is mainly related to the continuous fund raising and ongoing communication.
7. Stock-based compensation – Total \$1,466,334 (Increased by \$1,416,889)
  - During the six months ended March 31, 2018, the Company granted 8,050,000 incentive stock options (March 31, 2017 – 750,000)

The Company also reported receivables and prepaids for a total amount of \$633,613 (September 30, 2017 - \$776). The amount is broken down as follows:

		31-Mar-18	30-Sep-17
GST Receivable	\$	11,062	492
Interest Receivable		290	284
Prepaid expenses **		622,261	-
	\$	633,613	776

\*\* The Company was billed in advance for services ranging from 6 months to a year with respect to services primarily related to raising capital and public relations, specifically, internet marketing, research reports, news and press releases and their distribution. These amounts are recorded as prepaid and expensed on a monthly basis.

### **Shareholders Communication and Travel**

The Company reported shareholder communication and travel expenses totaling \$62,225 and broken down as follows:

		31-Mar-18	31-Mar-17
Communication & information	\$	9,119	\$ 6,401
Conferences		5,365	-
Press releases		10,728	3,000
Telephone & website		11,031	2,731
Travel & entertainment		25,982	4,690
	\$	62,225	\$ 16,822

### **Summary of Quarterly Results**

The following is a summary of the Company's financial results for the eight most recently completed quarters:

	<b><u>Q2 31-Mar-18</u></b>	<b><u>Q1 31-Dec-17</u></b>	<b><u>Q4 30-Sep-17</u></b>	<b><u>Q3 30-Jun-17</u></b>
	<b>IFRS</b>	<b>IFRS</b>	<b>IFRS</b>	<b>IFRS</b>
Net loss	(2,718,811)	(1,270,498)	(373,800)	(298,240)
Per Share	(0.01)	(0.01)	(0.01)	(0.005)
	<b><u>Q2 31-Mar-17</u></b>	<b><u>Q1 31-Dec-16</u></b>	<b><u>Q4 30-Sep-16</u></b>	<b><u>Q3 30-Jun-16</u></b>
	<b>IFRS</b>	<b>IFRS</b>	<b>IFRS</b>	<b>IFRS</b>
Net loss	(381,507)	(488,555)	(648,696)	(643,378)
Per Share	(0.005)	(0.01)	(0.025)	(0.025)

On February 9, 2016, the Company completed the acquisition of BSS Life Sciences ("BSS"). In connection with the closing, the Company issued 26,500,000 common shares to the shareholders of BSS (see note 10). As a result of the exchange, the transaction resulted in a reverse asset acquisition. Accordingly, BSS will be considered the continuing entity for accounting and financial reporting purposes and the Company, the continuing public company, being the corporation acquired. Therefore, all financial statements prior to the acquisition date are not presented in this report.

### ***Discussion***

**Six months ended March 31, 2018:**

For the six months ended March 31, 2018, please refer to Section 1.4 Results of Operations.

## 1.5 Liquidity

The Company has no current operating income or cash flow. In management's view, given the nature of the Company's operations, the most relevant financial information relates primarily to current liquidity, solvency and planned expenditures. The Company's financial success will be dependent on continuing to raise operating capital and successful clinical trials that validate the company's technology and such activities may take time to complete and the amount of resulting income is difficult to determine. The Company completed a non-brokered private placement through the issuance of 20,000,000 units for gross proceeds of \$1,000,000. Each Unit consists of one common share of the Company and one warrant ("Warrant"), each Warrant entitling the holder thereof to acquire one additional common share of the Company at a price of \$0.10 within 12 months. In addition, the following options and warrants were exercised.

In addition, the following options and warrants were exercised during the period ended March 31, 2018:

- i. issued 23,944,880 common shares from the exercise of acquisition warrants, finance warrants and finders' warrants, with prices ranging from \$0.12 to \$0.35 for total proceeds of \$3,462,694.
- ii. issued 5,375,000 common shares from the exercise of stock options, with prices ranging from \$0.06 to \$0.26 for total proceeds of \$898,000.

In the previous quarter, the Company reported that will need to raise an additional \$2.0M million, which is sufficient capital to execute the following key milestones:

- iii. Successfully recruit ten patients with non-muscle invasive bladder cancer to participate in the 1<sup>st</sup> in-human Research Study at the University of Rochester Medical Center;
- iv. Begin the study and validate previous bench test results that showed 1) physicians will be able to "see" the cancer in 10 minutes vs. one hour required by today's methods and 2) the white and florescence images will blend into one, placing the cancer in context within the bladder;
- v. Report research study results as information becomes available, which the Company believes will accelerate the momentum of the company's progress to-date;
- vi. Continue to redesign the prototype through Optel, Inc.;
- vii. Initiate FDA approval process;
- viii. Begin additional clinical trials as potentially required by the FDA.

On April 3, 2018, the Company announced the offering of a non-brokered private placement to raise up to \$3,500,000 through the distribution of units ("Units") at \$0.22 per Unit. Each Unit will consist of one common share and one common share purchase warrant, each warrant entitling the holder to acquire one additional common share at \$0.38 for 24 months.

On April 19, 2018, the Company closed its non-brokered Private Placement (Tranche 1 and 2) through the issuance of 17,919,820 units (the "Units") priced at \$0.22 per Unit for gross proceeds of \$3,942,361. Each Unit of this Private Placement will consist of one common share of the Company and one common share purchase warrant ("Warrant"), each Warrant entitling the holder to acquire one additional common share of the Company at a price of \$0.38 for 24 months from the date of issue.

As at March 31, 2018, the Company had \$3,147,797 in cash, \$5,750 in security deposits and \$633,613 in accounts receivable and prepaid expenses. The Company currently has no revenue being generated from its i/Blue system for the early detection of cancer. The Company believes that upon

completion of the prototype for manufacturability and the approval of the FDA, expected sales will start to generate in mid 2019.

The Company's historical capital needs have been met by equity subscriptions. On March 31, 2018, the Company had working capital of \$3,717,508 (September 30, 2017 – working capital deficiency of \$648,351).

Cash and cash equivalents

	<b>31-Mar-18</b>	<b>30-Sep-17</b>
Cash deposits	\$ 3,147,797	\$ 245,921
Total cash and cash equivalents	<b>\$ 3,147,797</b>	<b>\$ 245,921</b>

As at March 31, 2018, the Company held US\$222,432 (included in the above).

Credit Risk

Credit risk arises from cash held with banks and financial institutions. The maximum exposure to credit risk is equal to the carrying value of the financial assets. The Company's cash is held with a Canadian bank.

Currency Risk

Currency risk is the risk to the Company's earnings that arises from fluctuations of foreign exchange rates and the degree of volatility of these rates. The Company faces certain foreign exchange risks related to expenses incurred in U.S. dollars, a currency which may appreciate against the Canadian dollar, the Company's reporting currency. Additionally, net working capital balances denominated in non-reporting currencies are also subject to fluctuations in value. The Company mitigates these threats by limiting its exposure to such balances where their expenditure in the same non-reporting currency is not imminent.

Commitments

The Company has certain commitments related to the license agreement with Lawrence Livermore National Security. Please refer to Sections 1.2 Overall Performance – License Agreement.

**1.6 Capital Resources**

The Company's capital resources is fixed assets (computers & office equipment) with a book value of \$1,704 (\$2,005 – September 30, 2017).

**1.7 Off Balance Sheet Arrangements**

There are no off-balance sheet arrangements to which the Company is committed.

**1.8 Second Quarter**

The second quarter result does not differ significantly from other quarters, with the exception of the 5,000,000 shares issued to the President as management bonus.

**1.9 Transactions with Related Parties**

During the six months ended March 31, 2018, the Company paid or accrued \$1,380,188 (March 31, 2017 - \$229,909) to directors and officers or companies controlled by directors and officers of the Company, for management, accounting, and directors fees incurred by the Company.

		<b>31-Mar-18</b>	<b>31-Mar-17</b>
Management fees	\$	1,329,464	184,909
Accounting fees		36,974	36,000
Directors fees		13,750	4,500
<b>Total</b>	<b>\$</b>	<b>1,380,188</b>	<b>229,909</b>

During the six month ended March 31, 2018, the Company granted a total of 3,150,000 incentive stock options to the directors and officers at exercise prices ranging from \$0.18 to \$0.40, vesting immediately and expiring within 5 years. The fair value of the options granted ranged from \$0.1658 to \$0.2244 for total stock-based compensation of \$570,646.

Included in accounts payable are fees and expenses due to directors and officers in the amount of \$6,250 (September 30, 2017 - \$614,160), which are non-interest bearing, unsecured, and payable on demand. Fair value cannot be reliably determined.

### **1.10 Proposed Transactions**

N/A

### **1.11 Critical Accounting Estimates**

In preparing financial statements, management has to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Based on historical experience, current conditions and expert advice, management makes assumptions that are believed to be reasonable under the circumstances. These estimates and assumptions form the basis for judgments about the carrying value of assets and liabilities and reported amounts for revenues and expenses. Different assumptions would result in different estimates and actual results may differ from results based on these estimates. These estimates and assumptions are also affected by management's application of accounting policies. Critical accounting estimates are those that affect the consolidated financial statements materially and involve a significant level of judgment by management.

### **1.12 Financial and Other Instruments**

The carrying value of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and due from (to) related parties approximate their fair values due to the short maturity of those instruments.

### **1.13 Other**

Disclosure of Outstanding Share Capital: April 25, 2018

	<u>Number</u>
Common Shares	<u>126,084,738</u>

Disclosure of Outstanding Stock Options: April 25, 2018

	<u>Number</u>
Incentive Stock Options	<u>9,875,000</u>

Disclosure of Outstanding Share Purchase Warrants: April 25, 2018

	<u>Number</u>
Warrants	<u>36,825,577</u>
Fully diluted	<u>172,785,315</u>

## Disclosure Controls and Procedures

It should be noted that pursuant to Multilateral Instrument 52-511 (adopted by the British Columbia Securities Commission on November 23, 2007), that the officers of the Company are no longer required to certify the effectiveness of disclosure controls and procedures used by the Company, as was required in previous filings under National Instrument 52-109. Accordingly, the new forms of certificate to be signed by the Company's Chief Executive Officer and Chief Financial Officer contain the following Note to Reader:

In contrast to the certificate required under National Instrument 52-109 Certification of Disclosure in Issuers' Annual and Filings (NI 52-109), this Venture Issuer Basic Certificate does not include representations relating to the establishment and maintenance of disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as defined in NI 52-109. In particular, the certifying officers filing this certificate are not making any representations relating to the establishment and maintenance of:

- (i) controls and other procedures designed to provide reasonable assurance that information required to be disclosed by the issuer in its annual filings, filings or other reports filed or submitted under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and
- (ii) a process to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer's GAAP.

The issuer's certifying officers are responsible for ensuring that processes are in place to provide them with sufficient knowledge to support the representations they are making in this certificate.

Investors should be aware that inherent limitations on the ability of certifying officers of a venture issuer to design and implement on a cost effective basis DC&P and ICFR as defined in NI 52-109 may result in additional risks to the quality, reliability, transparency and timeliness of and annual filings and other reports provided under securities legislation.

## Subsequent Events

Subsequent to the six months ended March 31, 2018, the following occurred:

- On April 12, 2018, the Company closed Tranche 1 of the non-brokered private placement of 11,722,783 units (the "Units") priced at \$0.22 per Unit for gross proceeds of \$2,579,012. Each Unit of this Private Placement will consist of one common share of the Company and one common share purchase warrant ("Warrant"), each Warrant entitling the holder to acquire one additional common share of the Company at a price of \$0.38 for 24 months from the date of issue;
- On April 19, 2018, the Company closed Tranche 2 of the non-brokered private placement by issuing 6,197,037 Units at \$0.22 per Unit for proceeds of \$1,363,348. Each Unit of this Private Placement will consist of one common share of the Company and one common share purchase warrant ("Warrant"), each Warrant entitling the holder to acquire one additional common share of the Company at a price of \$0.38 for 24 months from the date of issue. This brought the total offering of the two tranches to 17,919,820 Units for aggregate gross proceeds of \$3,942,360. The placement has been oversubscribed, resulting in the issuance of an additional 2,010,729 Units for \$442,360.
- Total finders' fees will be paid in the form of cash in the amount of \$223,267 and 1,117,110 finders' warrants (exercisable at \$0.38 per share for 24 months). All securities issued will be subject to a four-month hold period.

- The Company also announced today that, pursuant to the Company's Stock Option Plan, an aggregate of 2,750,000 options have been granted to certain directors, officers and consultants. The options are exercisable at \$.31 per share for a period of five years.
- 1,050,000 warrants with an exercise price of \$0.10 were exercised for total proceeds of \$105,000.

Additional information

Additional information relating to the company is on SEDAR at [www.sedar.com](http://www.sedar.com).